Vaccine
EpiVacCorona-N
Developer
Vector State Scientific Center for Virology and Biotechnology of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor)
Производитель
Vector State Scientific Center for Virology and Biotechnology; production complexes of Vektor-BiAlgam JSC and GEROPHARM LLC
Status
Date of government registration: August 26, 2021
EpiVacCorona-N began Phase I and II clinical trials on April 8, 2021. These stages assess the safety, tolerance, reactogenicity and immunogenicity of the vaccine. Planned sample of volunteers: 300.
End date of Phase I and II clinical trials: September 30, 2021.
Key information
What’s in the vaccine?
Like the original EpiVacCorona, it is based on a carrier protein and artificially synthesized peptides: small fragments of the SARS-CoV-2 virus’ spike proteins. The only difference is that two of the three peptides were combined into a single one. This does not affect their immunogenic qualities and was done in order to optimize vaccine production.
